StockUS listing USORYZFPINKHealthcareValue Trap

Oryzon Genomics S.A(ORYZF) Stock Analysis | Healthcare

USD --+0.00%
Reward40Moderate
Risk54Moderate
75%Data
Thin -37% profit margin
USD —+0.00 (+0.00%) Previous close · PINK
Market cap 292.99M
Reward Ratingⓘ40 Moderate reward assessment · 75% data coverage
Bottom 10% of stocksView factors
Risk Ratingⓘ54 Moderate risk assessment
Risk factors availableUnlock details

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

Educational tool only · More
Limited data coverage
We don't have enough public data on ORYZF to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available yet for this stock
The overview tab requires data we don't have for this stock yet. The price chart is the most reliable view we have — try the Chart tab.
Earnings Ex-dividend

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

What is Oryzon Genomics S.A?

, a clinical stage biopharmaceutical company, engages in the discovery and development of epigenetics-based therapeutics for patients with cancer and CNS (central nervous system) disorders.

AI Brief Pro

The brief on Oryzon Genomics S.A

The story behind the price, the case for and against, and what could go wrong. Open a part to read it.

What is Oryzon Genomics S.A?

, a clinical stage biopharmaceutical company, engages in the discovery and development of epigenetics-based therapeutics for patients with cancer and CNS (central nervous system) disorders. Its clinical phase compounds include iadademstat (ORY-1001), a selective LSD1 inhibitor that is in Phase II trials for oncology; and vafidemstat (ORY-2001), a CNS-optimized LSD1 inhibitor, which is in Phase II trials for the treatment of CNS and psychiatric diseases. The company is listed on the PINK in USA, operating in the Healthcare sector, with a market capitalisation of 292.99M.

Financial Highlights

Investment Breakdown

Growth
Moderate growth momentum — positive trajectory without breakout acceleration.
Profitability
Thin or inconsistent margins weigh on earnings quality.
Risk
Risk profile appears balanced versus broad market conditions.
Valuation
Valuation is less clear with a negative earnings base.

OpenBook Logo Analysis

Reward: Moderate (40)
Company Information
SectorHealthcare
IndustryBiotechnology
Market Cap292.99M
Beta0.364
Insider Activity
12M windowNo data
No insider activity data available for this ticker.